UK markets close in 57 minutes

Conduit Pharmaceuticals Inc. (CDT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.18000.0000 (0.00%)
As of 04:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.1800
Open3.0050
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.1800 - 3.1800
52-week range0.9500 - 25.0000
Volume15
Avg. volume35,898
Market cap234.778M
Beta (5Y monthly)2.45
PE ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

    Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the appointment of Dr. Joanne Holland as Chief Scienti

  • GlobeNewswire

    Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub

    SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company for portfolio expansion, enhanced development capabilities, and growth of

  • GlobeNewswire

    Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

    SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model for compound development, today announced CEO Dr. David Tapolczay, will be participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, being held February 13-14, 2024. Dr. Tapolczay is scheduled to present on Wednesday, February 14, 2024, at 8:00 am EST/13:30 GMT, and will be particip